Skip to main content
Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Aphria affiliate Tetra Bio-Pharma Launching Sales in EU:👈
Aphria owns a large stake in TBP and is a partner with them producing their PPP001 3-strains cannabis which is being studied in clinical trials to create a first for prescription markets: Prescription Cannabis. But the company isn't waiting for the prescription market. They've recently brought Dania Scott on board from Canopy Growth Corporation to handle sales, and she's been made managing director of ENJOUCA, which is marketing PPP001 as a MMJ product in Canada, EU and US markets, not in that particular order, necessarily. They have recently purchased a number of corresponding domain names like,, and Prior to this, the company has been focusing PPP001 as the first prescription drug smokable cannabis, but now is also moving it into the non-prescription MMJ market.

LOI Signed With Danish Cannabis Distributor for Multiple Products:
Today the affiliated company announced a letter of intent (LOI) with a Danish cannabis company, DanCann Pharma, for distribution of ENJOUCA (non-prescription PPP001) and QIXLEEF (prescription PPP001) in multiple countries (Denmark, Norway, Sweden, Finland, and Germany). They put a very conservative estimate on annual sales for 2026 as $55 million DKK. Along with the PPP001 drug products, the danish firm will also be handling sales of Tetra's Dronabinol Reduvo Adversa brand, which is delivered through the mucous membranes (muco-adhesive) which is a great advancement over regular dronabinol, with greater delivery percentages to patients with far less adverse events. The estimates do not consider revenue from neighboring EU countries, which are part of Tetra's overall EU target market. Tetra also has two other dronabinols that could be entered into those markets, one being an inhaled dronabinol, which bypasses the first-pass liver metabolism and problems associated with that. Another is dronabinol soft gels, which was also not mentioned in today's news. Quoting DanCann, "We estimate the first sale to commence during second half of 2021, leaving us sufficient time to prepare our sales organization. DanCann estimates reaching peak (annual) sales of $55M DKK by 2026" (about $11.5M CDN).👈

An Improved Dronabinol, Prescription Dried Cannabis and a Non-Prescription Dried Cannabis:
Along with expected sales, the company disclosed that the agreement encompasses a sum of upfront and milestone payments of up to $2,25M CDN and a confidential royalty level on DanCann net sales for Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™. Quoting Tetra about Reduvo, "It is indicated for the treatment of patients living with Chemotherapy-Induced Nausea and Vomiting (CINV) as well as those suffering from AIDS-related anorexia associated with weight loss. The Reduvo™ Adversa® technology will allow DanCann to launch a largely improved version of dronabinol in the Nordic countries & Germany.👈 The clinical benefits are numerous including: limited first-pass metabolism leading to an improved bioavailability and consequently to a reduced gastro-intestinal exposure and side-effects." According to Tetra's CCO, Steeve Neron, "Physicians and other healthcare professionals are receptive to cannabinoid-derived medicines but have been seeking robust scientific evidence supported by a traditional pharma infrastructure such as a pharmacovigilance program, medical information, medical science liaisons, and so on." Tetra provides such evidence.

Just The Beginning:
This is just the beginning of sales of these products in Europe and in other markets. As the company gets its feet wet for the first time with real revenues, it's expected they start rolling out to other markets in a natural manner. Other deals are in progress and/or negotiations, depending on their own unique circumstances, and will occur accordingly, I expect. This news causes things to gel and come together, crystalize into a logistical flowing network, and expand to more markets. As further permissions are granted, we should have further announcements of further deals as Tetra seems bound and determined to implement this new launch, not just through DanCann but througout EU, CAN and USA.

In Other News: CB2 Therapeutics, a Tetra JV Company:
In other news that was not announced by PR but by SEDAR filing, Tetra's co-owned JV with Thorne Research (Onegevity), called CB2 Therapeutics, had major advances in 2020, just revealed in Tetra's regulatory filing February 17, 2021. "TALLC Corporation Inc. Development of fast onset, long duration, and an alternative to opioid medications and NSAID drugs👈 for ocular pain and dry eye disease market using TBP’s key asset HU-308👈." For more on Tetra's HU-308, see

TALLC Corporation Inc.👈
"On January 8, 2020, the Company formed TALLC Corporation Inc. (“TALLC”), a shared venture with Altus Formulations (“Altus”) to develop a series of therapeutics using HU-308 to create new intellectual property for ophthalmic products. As of the date of this MD&A, Tetra had contributed $1,250,000 and now owns 50% of TALLC while Altus owns the remaining 50%. With initial funding provided from Altus and Tetra, TALLC’s immediate focus is to develop TA-A001, a non-opioid, non-steroidal small molecule that selectively activates CB2 receptors mediating the human anti-inflammatory response. Combined with TALLC’s novel SmartCelleTM nanotechnology, TA-A001 is expected to provide fast onset, long duration and can be an alternative to opioid medications and NSAID drugs in the multibillion-dollar ocular pain and dry eye disease market."

?? Also, this is important to know, too:
TALLC has combined TA-A001 with its SmartCelleTM nanotechnology to create TALLC Formulation TA-P2005. Preclinical studies have indicated this formulation was 12 times more efficacious than the conventionally formulated drug used as a control, supporting the hypothesis that SmartCelleTM increases corneal access.

?? Additionally, TALLC is working on several studies to determine the analgesic and anti-inflammatory effects of increasing doses of formulations of TA-A001 in a corneal hyperalgesia model.</p>

?? TALLC also began discussions to explore the value of TA-A001 and TA-A002, a topical treatment, in treating the glaucoma and dry-eye disease.

?? TALLC continues to focus on its lead indication, the orphan disease keratoconus and is expected to shortly submit its application for orphan drug status.👈

Also, Tetra notes further: UK Patent GB2561009 Granted, Dalton Pharma Contracted
"On July 7, 2020, United Kingdom Intellectual Property Office granted TALLC patent, GB2561009, for its novel SmartCelleTM nanotechnology. It is the first in the series of SmartCelleTM “smart micelle” patents and is a critical addition to TALLC’s growing patent portfolio. The North American and European (patent) applications are now under review and are proceeding as expected. SmartCelleTM nanotechnology is expected to allow delivery of highly insoluble molecules and is designed to provide improved access to cornea and the back of the eye. The novel SmartCelleTM TA-A001 formulation had already demonstrated potency in models of ocular pain and inflammation and was transferred for manufacturing to Dalton Pharma Services, a contract development and manufacturing organization."

There is just so much going on with all these Tetra companies. Keep it in mind what TALLC is accomplishing with HU308. Keep in mind what research been going on in hundreds of peer-reviewed studies worldwide.
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.